CA3139943A1 - Genome-based methods for reducing cardiovascular risk - Google Patents

Genome-based methods for reducing cardiovascular risk Download PDF

Info

Publication number
CA3139943A1
CA3139943A1 CA3139943A CA3139943A CA3139943A1 CA 3139943 A1 CA3139943 A1 CA 3139943A1 CA 3139943 A CA3139943 A CA 3139943A CA 3139943 A CA3139943 A CA 3139943A CA 3139943 A1 CA3139943 A1 CA 3139943A1
Authority
CA
Canada
Prior art keywords
genetic variants
patient
prs
cad
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139943A
Other languages
English (en)
French (fr)
Inventor
Amy DAMASK
Charles Paulding
Aris BARAS
Goncalo Abecasis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3139943A1 publication Critical patent/CA3139943A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
CA3139943A 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk Pending CA3139943A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849670P 2019-05-17 2019-05-17
US62/849,670 2019-05-17
US201962933181P 2019-11-08 2019-11-08
US62/933,181 2019-11-08
PCT/US2020/033315 WO2020236670A1 (en) 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk

Publications (1)

Publication Number Publication Date
CA3139943A1 true CA3139943A1 (en) 2020-11-26

Family

ID=70978651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139943A Pending CA3139943A1 (en) 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk

Country Status (6)

Country Link
US (2) US12264366B2 (https=)
EP (2) EP3969620B1 (https=)
JP (2) JP2022532423A (https=)
CA (1) CA3139943A1 (https=)
MX (1) MX2021014015A (https=)
WO (1) WO2020236670A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116171161A (zh) 2020-08-25 2023-05-26 雷杰纳荣制药公司 用pcsk9和ldlr调节剂治疗败血症
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EP2158330A2 (en) * 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JP5526122B2 (ja) 2008-04-18 2014-06-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 主要有害心イベントのリスクを予測する方法
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
JP2015507205A (ja) * 2012-02-12 2015-03-05 ビージー メディシン，インコーポレイテッド 有害事象のリスク因子および予測
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JP6450679B2 (ja) 2012-08-21 2019-01-09 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10337070B2 (en) * 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20190017119A1 (en) * 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor

Also Published As

Publication number Publication date
US20210002724A1 (en) 2021-01-07
EP4640848A2 (en) 2025-10-29
JP2026062658A (ja) 2026-04-10
US20250257406A1 (en) 2025-08-14
US12264366B2 (en) 2025-04-01
EP3969620A1 (en) 2022-03-23
EP3969620B1 (en) 2025-06-25
MX2021014015A (es) 2022-02-21
WO2020236670A1 (en) 2020-11-26
EP4640848A3 (en) 2026-01-14
JP2022532423A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
Walsh et al. Genome-wide association studies of cardiovascular disease
US20250257406A1 (en) Genome-Based Methods For Reducing Cardiovascular Risk
Van der Meer et al. Boosting schizophrenia genetics by utilizing genetic overlap with brain morphology
Taylor et al. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
Moll et al. Precision approaches to chronic obstructive pulmonary disease management
JP2021072775A (ja) 染色体相互作用の検出
Sivapalaratnam et al. Monocyte gene expression signature of patients with early onset coronary artery disease
Bruno et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure
Miller et al. Precision medicine approaches to vascular disease: JACC Focus Seminar 2/5
Sasidhar et al. Genetics of coronary artery disease–A clinician's perspective
Yang et al. Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar dna-binding profiles in vivo
Schneider Target therapy in SLE
Chang et al. A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity
Lekka et al. Literature analysis for systematic drug repurposing: a case study from Biovista
Hildebrandt et al. The dual pro-inflammatory and bone-protective role of calcitonin gene-related peptide alpha in age-related osteoarthritis
Lu et al. Identifying causes of fracture beyond bone mineral density: evidence from human genetics
Satny et al. Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia
HK40130500A (en) Genome-based methods for reducing cardiovascular risk
Mueller et al. Small-RNA sequencing identifies serum microRNAs associated with abnormal electrocardiography findings in patients with Chagas disease
JP7018544B2 (ja) 心房細動の処置のためのブシンドロールを伴う方法および組成物
Ichimura et al. Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy
SCALLOP consortium et al. Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets
Mishra et al. Gene set analysis of transcriptomics data identifies new biological processes associated with early markers of atherosclerosis but not with those of osteoporosis: Atherosclerosis-osteoporosis co/multimorbidity study in the Young Finns Study
EP0939136A1 (en) Assay for predicting the angiographic response to lipid-lowering therapy in patients
Young et al. Will genetic data significantly change cardiovascular risk prediction in daily practice?

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260422